Treatment of CLL with TP53 Mutation and/or 17p Deletion in Treatment-Naive Patients
Patients with treatment-naive chronic lymphocytic leukaemia who carry a TP53 mutation and/or 17p deletion represent a distinct high-risk sub-population. The presence of TP53 disruption significantly influences the choice of first-line therapy.
Clinical scenario
This protocol applies to treatment-naive CLL with confirmed TP53 mutation and/or 17p deletion. These genomic findings are associated with a poor response to conventional chemoimmunotherapy, making targeted agent selection particularly important.
Treatment approach (partial overview)
First-line options in this setting centre on targeted agents, with continuous covalent BTK inhibitor (cBTKi) therapy as the preferred approach. Additional fixed-duration combination regimens are available as licensed alternatives, and venetoclax monotherapy is reserved for specific situations.
The complete regimen selection criteria, preferred agents, and alternative pathways are detailed in the full protocol.
References
- First-line treatment options for CLL patients with TP53 disruption include BTKi treatment and venetoclax monotherapy (the latter only where BTKi are contraindicated).
- Continuous cBTKi regimens may be preferred over fixed-duration regimens due to the longer responses observed in this setting (GRADE 2A).
- Among continuous treatment options, second-generation cBTKi (acalabrutinib or zanubrutinib) are preferred to ibrutinib due to their improved safety profile (GRADE 1A).
- Ibrutinib is not recommended for new treatment initiation but may be continued in patients already receiving it and tolerating it well.
- Acalabrutinib–obinutuzumab (A+O, MHRA [no NICE TA/SMC], FDA, EMA) is a first-line option for patients with TP53 disruption (GRADE 1B).
- Venetoclax monotherapy remains an option for patients for whom a BTKi or idelalisib–rituximab is contraindicated (GRADE 2B).
- Idelalisib–rituximab is least preferred due to higher toxicity (GRADE 2A).
View source ↗